Monday, November 23, 2026

Moderna and Merck's Personalized mRNA Cancer Therapy Succeeds in Phase 3 Trial, Sending Stock Up 177%

Input
2026-08-20 08:32:29
Updated
2026-08-20 08:32:29
Logos of Moderna and Merck. Yonhap News

[Financial News] Moderna and Merck, the U.S. pharmaceutical companies that jointly developed a personalized mRNA cancer vaccine, said on the 19th (local time) that the therapy met its main goal in a late-stage (Phase 3) clinical trial in high-risk melanoma patients by suppressing cancer recurrence and metastasis.
It is the first time a personalized cancer therapy based on messenger ribonucleic acid (mRNA) technology, which was used in COVID-19 vaccines, has produced positive results in a large-scale Phase 3 trial.
The two companies conducted the trial in more than 1,100 high-risk patients who had undergone surgery to remove melanoma.
As a result, the group that received the personalized vaccine "Intismeran" together with Merck's immunotherapy drug "Keytruda" saw a significant extension in the time before the cancer returned compared with the Keytruda-only group. The combination also met a secondary goal of reducing the risk that the cancer would spread to other organs.
Researchers said the results could mark a new paradigm in precision immunotherapy, in which treatment is designed around the characteristics of each patient's tumor. The therapy, called "Intismeran autogene" (development code V940, mRNA-4157/V940), was designed to target up to 34 neoantigens found in each patient's tumor.
The Wall Street Journal (WSJ) said the findings open the door to developing a new treatment that could help prevent recurrence in melanoma patients and extend survival.
The two companies are discussing the application process with regulators, aiming for market approval in 2027.
Following the news of the trial success, Moderna shares on the New York Stock Exchange (NYSE) closed at $174.38, up 177% from the previous day. Trading volume was about 18 times the three-month average.
The gain marked the biggest one-day increase for any S&P 500 Index constituent in the past 25 years. Moderna shares extended their strength in after-hours trading, rising another 1.50%.
Analysts said Moderna, which had been sluggish since the COVID-19 vaccine boom, has now laid the groundwork for entering the $240 billion cancer drug market.
The market is also looking at the broader potential for nine follow-up trials now under way across six cancer types, including not only melanoma but also lung, bladder, kidney, pancreatic and stomach cancers. Merck shares also closed at $152.20, up 12.6%, setting a new all-time high.
[email protected] Lee Seok-woo, international affairs Reporter